NZ732073A - Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof - Google Patents

Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Info

Publication number
NZ732073A
NZ732073A NZ732073A NZ73207315A NZ732073A NZ 732073 A NZ732073 A NZ 732073A NZ 732073 A NZ732073 A NZ 732073A NZ 73207315 A NZ73207315 A NZ 73207315A NZ 732073 A NZ732073 A NZ 732073A
Authority
NZ
New Zealand
Prior art keywords
adcc
fusion gene
synthetic fusion
peptide technology
universal
Prior art date
Application number
NZ732073A
Other languages
English (en)
Inventor
Chiang Li
Shyam Unniraman
Original Assignee
1Globe Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co Ltd filed Critical 1Globe Biomedical Co Ltd
Publication of NZ732073A publication Critical patent/NZ732073A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ732073A 2014-12-08 2015-12-08 Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof NZ732073A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462089097P 2014-12-08 2014-12-08
US201562200557P 2015-08-03 2015-08-03
PCT/US2015/064572 WO2016094456A1 (en) 2014-12-08 2015-12-08 Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Publications (1)

Publication Number Publication Date
NZ732073A true NZ732073A (en) 2019-04-26

Family

ID=56108081

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ732073A NZ732073A (en) 2014-12-08 2015-12-08 Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Country Status (11)

Country Link
US (2) US12247062B2 (OSRAM)
EP (1) EP3230311B1 (OSRAM)
JP (2) JP7095992B2 (OSRAM)
KR (1) KR102654033B1 (OSRAM)
CN (1) CN107108718B (OSRAM)
AU (1) AU2015360642B2 (OSRAM)
CA (1) CA2968987C (OSRAM)
NZ (1) NZ732073A (OSRAM)
RU (1) RU2725807C2 (OSRAM)
SG (1) SG11201704124YA (OSRAM)
WO (1) WO2016094456A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
NZ732073A (en) 2014-12-08 2019-04-26 1Globe Biomedical Co Ltd Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
JP2021524467A (ja) * 2018-05-23 2021-09-13 メニスマート セラピューティクス， インコーポレイテッドＭａｎｙｓｍａｒｔ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 二重特異性ｔ細胞誘導体及びその使用
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
EP4173640A4 (en) * 2020-06-30 2024-08-14 GAIA BioMedicine Inc. METHOD FOR STABILIZING THE BINDING OF AN ANTIBODY ON AN NK CELL AND ASSOCIATED USE

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
IL101147A (en) * 1991-03-07 2004-06-20 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
ES2176574T3 (es) * 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
KR101063278B1 (ko) * 1998-08-11 2011-09-07 바이오겐 아이덱 인크. Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
EP1355942B1 (en) * 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
IL158969A0 (en) * 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
KR101130181B1 (ko) * 2003-02-27 2012-03-28 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 인플루엔자 바이러스 감염의 치료 및 검출에 유용한 핵산분자, 폴리펩티드, 항체 및 이를 포함하는 조성물
WO2004108158A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-cd3 antibody
KR20120125634A (ko) * 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
KR20060131892A (ko) * 2004-02-16 2006-12-20 마이크로메트 에이지 덜 면역원성인 결합 분자
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
JP2010516769A (ja) * 2007-01-23 2010-05-20 ザイモジェネティクス， インコーポレイテッド 炎症を軽減するための可溶性ＦｃγＲＩＡ
US8043621B2 (en) * 2007-05-10 2011-10-25 Ramot At Tel Aviv University Ltd. Recombinant fusion protein and polynucleotide construct for immunotoxin production
US20120294857A1 (en) 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein
BR112013016235B1 (pt) * 2010-12-22 2020-03-31 Cephalon Australia Pty Ltd Anticorpo isolado, uso de um anticorpo, ácido nucleico, célula transformada e composição farmacêutica
KR20150031217A (ko) * 2011-12-15 2015-03-23 더 로얄 인스티튜션 포 디 어드밴스먼트 오브 러닝/맥길 유니버시티 가용성 igf 수용체 fc 융합 단백질 및 이의 용도
MX353382B (es) * 2012-03-01 2018-01-10 Amgen Res Munich Gmbh Moleculas de union polipeptido de larga duracion.
NZ732073A (en) 2014-12-08 2019-04-26 1Globe Biomedical Co Ltd Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Also Published As

Publication number Publication date
AU2015360642A1 (en) 2017-06-08
EP3230311A4 (en) 2018-05-30
US12247062B2 (en) 2025-03-11
AU2015360642B2 (en) 2019-04-04
US20170362299A1 (en) 2017-12-21
RU2725807C2 (ru) 2020-07-06
SG11201704124YA (en) 2017-06-29
WO2016094456A1 (en) 2016-06-16
US20220235115A1 (en) 2022-07-28
CN107108718A (zh) 2017-08-29
JP7095992B2 (ja) 2022-07-05
CA2968987A1 (en) 2016-06-16
JP2018502068A (ja) 2018-01-25
KR102654033B1 (ko) 2024-04-02
JP2021035994A (ja) 2021-03-04
RU2017124141A (ru) 2019-01-10
CN107108718B (zh) 2022-07-22
EP3230311B1 (en) 2022-01-26
RU2017124141A3 (OSRAM) 2019-06-19
CA2968987C (en) 2022-05-10
KR20170089003A (ko) 2017-08-02
EP3230311A1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
MX2023007045A (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos.
PH12018502400A1 (en) Anti-tim-3 antibodies and methods of use thereof
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
WO2015109124A3 (en) Immunomodulatory agents
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MY181199A (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2018002315A (es) Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos.
NZ732073A (en) Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
MX2017004542A (es) Inmunomoduladores.
WO2015138870A3 (en) Compositions and methods for targeted epigenetic modification
SG10201806108TA (en) Binding proteins and methods of use thereof
CA2904014C (en) Modified t lymphocytes having improved specificity
MY192824A (en) Compound targeting il-23a and tnf-alpha and uses thereof
EP4306166A3 (en) Compounds, compositions and methods of use
PH12016501441B1 (en) Chimeric alkaline phosphatase-like proteins
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
WO2015106043A3 (en) Novel synthetic biology-based adcc technology
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
EP4285930A3 (en) Protein formulations
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2020 BY JING LEI

Effective date: 20191204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2021 BY JING LEI

Effective date: 20201117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2022 BY PAVIS PAYMENT GMBH

Effective date: 20211201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2023 BY JING LEI

Effective date: 20221111

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 DEC 2024 BY JING LEI

Effective date: 20231114

LAPS Patent lapsed